US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
ATE218889T1
(de)
*
|
1990-11-09 |
2002-06-15 |
Stephen D Gillies |
Cytokine immunokonjugate
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
EP0556328A4
(en)
*
|
1990-11-09 |
1994-06-08 |
Abbott Lab |
Bridging antibody fusion constructs
|
PT706799E
(pt)
*
|
1994-09-16 |
2002-05-31 |
Merck Patent Gmbh |
Imunoconjugados ii
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5817789A
(en)
|
1995-06-06 |
1998-10-06 |
Transkaryotic Therapies, Inc. |
Chimeric proteins for use in transport of a selected substance into cells
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
AU1952497A
(en)
*
|
1996-02-13 |
1997-09-02 |
Regents Of The University Of California, The |
Novel antibody-cytokine fusion protein, and methods of making and using the same
|
CA2309766C
(en)
|
1997-11-20 |
2008-09-30 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
WO1999047538A1
(en)
|
1998-03-19 |
1999-09-23 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
GB9822763D0
(en)
*
|
1998-10-20 |
1998-12-16 |
Univ Sheffield |
Immunoglobin variant
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
ATE316982T1
(de)
|
1999-08-09 |
2006-02-15 |
Lexigen Pharm Corp |
Mehrere zytokin-antikörper komplexen
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
WO2002002641A1
(en)
|
2000-06-16 |
2002-01-10 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to blys
|
EP2338512A1
(de)
|
2000-11-28 |
2011-06-29 |
MedImmune, LLC |
Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
CA2437811A1
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
EP1385864B1
(de)
|
2001-04-13 |
2010-06-09 |
Human Genome Sciences, Inc. |
Anti-VEGF-2 Antikörper
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
NZ529359A
(en)
|
2001-05-25 |
2007-04-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
US7045543B2
(en)
|
2001-11-05 |
2006-05-16 |
Enzrel Inc. |
Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
|
WO2003086458A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
EP1506286B1
(de)
|
2002-05-24 |
2014-03-19 |
Merck Sharp & Dohme Corp. |
Neutralisierung eines menschlichen anti-igfr-antikörpers
|
CA2488682C
(en)
|
2002-06-10 |
2014-04-01 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
KR101106441B1
(ko)
|
2003-03-19 |
2012-01-18 |
바이오겐 아이덱 엠에이 인코포레이티드 |
노고 수용체 결합 단백질
|
WO2004101764A2
(en)
|
2003-05-13 |
2004-11-25 |
Chiron Corporation |
Methods of modulating metastasis and skeletal related events resulting from metastases
|
US7326567B2
(en)
|
2003-11-12 |
2008-02-05 |
Schering Corporation |
Plasmid system for multigene expression
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
PL1711528T3
(pl)
|
2003-12-23 |
2012-11-30 |
Genentech Inc |
Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
|
JP2007517506A
(ja)
|
2004-01-05 |
2007-07-05 |
イーエムディー・レキシゲン・リサーチ・センター・コーポレーション |
標的化用化合物
|
AU2005212435B2
(en)
|
2004-02-10 |
2010-09-09 |
Biomarin Pharmaceutical Inc. |
Acid alpha-glucosidase and fragments thereof
|
PL1776136T3
(pl)
|
2004-06-24 |
2013-03-29 |
Biogen Ma Inc |
Leczenie stanów związanych z demielinizacją
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
DE602005025685D1
(de)
|
2004-12-03 |
2011-02-10 |
Schering Corp |
Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
|
EP1836161B1
(de)
|
2004-12-22 |
2016-07-20 |
BHI Limited Partnership |
Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
|
WO2006078776A2
(en)
|
2005-01-19 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
JP2009502123A
(ja)
|
2005-07-08 |
2009-01-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Sp35抗体およびその使用
|
WO2007008604A2
(en)
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
HUE026423T2
(en)
|
2005-11-04 |
2016-05-30 |
Genentech Inc |
Use of complement biosynthetic pathway inhibitors for treating eye diseases
|
NZ568762A
(en)
|
2005-11-07 |
2011-11-25 |
Scripps Research Inst |
Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
|
US20090175872A1
(en)
|
2005-12-02 |
2009-07-09 |
Biogen Idec Ma Inc. |
Treatment of Conditions Involving Demyelination
|
CA2640423C
(en)
|
2006-01-27 |
2016-03-15 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
WO2007120787A2
(en)
|
2006-04-13 |
2007-10-25 |
Novartis Vaccines & Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
|
SG172684A1
(en)
|
2006-06-07 |
2011-07-28 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
PL2292663T3
(pl)
|
2006-08-28 |
2014-03-31 |
Kyowa Hakko Kirin Co Ltd |
Antagonistyczne ludzkie przeciwciała monoklonalne swoiste wobec ludzkiego LIGHT
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
PL2089417T3
(pl)
|
2006-10-12 |
2015-07-31 |
Bhi Lp |
Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
|
US7935791B2
(en)
|
2006-12-18 |
2011-05-03 |
Genentech, Inc. |
Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
|
LT2436696T
(lt)
|
2007-01-05 |
2017-08-25 |
University Of Zurich |
Anti-beta-amiloido antikūnas ir jo panaudojimas
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
KR101496479B1
(ko)
|
2007-01-09 |
2015-02-26 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Sp35 항체 및 그의 용도
|
GEP20135853B
(en)
|
2007-02-02 |
2013-06-25 |
Univ Pierre And Marie Curie |
Method of myelination and oligodendrocyte differentiation promotion
|
JP2010521180A
(ja)
|
2007-03-14 |
2010-06-24 |
ノバルティス アーゲー |
癌を処置、診断または検出するためのapcdd1阻害剤
|
WO2008134046A1
(en)
|
2007-04-27 |
2008-11-06 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-cd4 antibodies
|
PT2195023T
(pt)
|
2007-08-29 |
2018-06-08 |
Sanofi Sa |
Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
SI3002298T1
(sl)
|
2007-11-21 |
2019-12-31 |
Oregon Health & Science University |
Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe
|
WO2009079649A1
(en)
|
2007-12-18 |
2009-06-25 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
CN101932333A
(zh)
|
2007-12-26 |
2010-12-29 |
瓦西尼斯公司 |
抗c35抗体联合疗法和方法
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
DK2288358T3
(en)
|
2008-04-16 |
2016-01-11 |
Biogen Ma Inc |
A method of isolating antibodies using polyalkylene glycol and transition metals
|
BRPI0912225A2
(pt)
|
2008-05-07 |
2018-03-20 |
Zystor Therapeutics, Inc. |
peptídeos de direcionamento lisossomais e usos dos mesmos
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
KR101442323B1
(ko)
|
2008-09-07 |
2014-09-25 |
글라이코넥스 인코포레이티드 |
항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
|
WO2010035261A2
(en)
|
2008-09-29 |
2010-04-01 |
Ben Gurion University Of The Negev Research And Development Authority |
Amyloid beta-peptides and methods of use thereof
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
JP5810413B2
(ja)
|
2008-12-19 |
2015-11-11 |
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー |
ヒト抗アルファシヌクレイン自己抗体
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
EP2405920A1
(de)
|
2009-03-06 |
2012-01-18 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue therapie gegen angstzustände
|
EP2233500A1
(de)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimierte Fc Varianten
|
US8524869B2
(en)
|
2009-03-24 |
2013-09-03 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against LIGHT and uses thereof
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
MX2011011044A
(es)
|
2009-04-22 |
2011-11-04 |
Merck Patent Gmbh |
Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
|
NZ618067A
(en)
|
2009-05-08 |
2015-07-31 |
Vaccinex Inc |
Anti-cd100 antibodies and methods for using the same
|
DK2437767T3
(en)
|
2009-06-01 |
2015-09-28 |
Medimmune Llc |
MOLECULES WITH EXTENDED half-lives and uses thereof
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011056997A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
EP2561076A1
(de)
|
2010-04-19 |
2013-02-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulation von xrn1
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
AU2011274472B2
(en)
|
2010-07-09 |
2017-03-30 |
Janssen Vaccines & Prevention B.V. |
Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
|
WO2012025636A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
CN103347896B
(zh)
|
2010-09-02 |
2017-06-13 |
瓦西尼斯公司 |
抗cxcl13抗体和其使用方法
|
WO2012032143A1
(en)
|
2010-09-10 |
2012-03-15 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
SG189174A1
(en)
|
2010-10-11 |
2013-05-31 |
Biogen Idec Internat Neuroscience Gmbh |
Human anti-tau antibodies
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
KR101947356B1
(ko)
|
2010-11-23 |
2019-02-12 |
글락소 그룹 리미티드 |
온코스타틴 m (osm)에 대한 항원 결합 단백질
|
CA2818621A1
(en)
|
2010-11-24 |
2012-05-31 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting hgf
|
JP6067575B2
(ja)
|
2010-12-17 |
2017-01-25 |
ニューリミューン ホールディング エイジー |
ヒト抗sod1抗体
|
JP2014510730A
(ja)
|
2011-03-16 |
2014-05-01 |
サノフイ |
デュアルv領域抗体様タンパク質の使用
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
SI2723379T1
(sl)
|
2011-06-23 |
2019-03-29 |
Biogen International Neuroscience Gmbh |
Molekule, ki se vežejo ma anti alfa-sinuklein
|
US9499612B2
(en)
|
2011-07-27 |
2016-11-22 |
Glaxo Group Limited |
Antigen binding constructs
|
EP2753697A1
(de)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
RS60828B1
(sr)
|
2011-10-11 |
2020-10-30 |
Viela Bio Inc |
Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
EP2776838A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Frühe diagnose neurodegenerativer erkrankungen
|
EP2788379B1
(de)
|
2011-12-05 |
2020-02-05 |
X-Body, Inc. |
Pdgf-rezeptor beta bindende polypeptide
|
EP2794653B1
(de)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
AU2013225812B2
(en)
|
2012-03-02 |
2017-11-30 |
Vaccinex, Inc. |
Methods for the treatment of B cell-mediated inflammatory diseases
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
UY34682A
(es)
|
2012-03-28 |
2013-10-31 |
Sanofi Sa |
Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
|
JP6280031B2
(ja)
*
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
EP2847216A1
(de)
|
2012-05-07 |
2015-03-18 |
Sanofi |
Verfahren zur verhinderung einer biofilmbildung
|
MX2014013950A
(es)
|
2012-05-14 |
2015-02-17 |
Biogen Idec Inc |
Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
US9290564B2
(en)
|
2012-05-24 |
2016-03-22 |
Mountgate Group Limited |
Compositions and methods related to the prevention and treatment of rabies infection
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
EP2869818A1
(de)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
|
EP2888279A1
(de)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti-lrp6-antikörper
|
AU2013306390B2
(en)
|
2012-08-24 |
2018-07-05 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
SG10201705104UA
(en)
|
2012-12-21 |
2017-07-28 |
Biogen Int Neuroscience Gmbh |
Human anti-tau antibodies
|
EP3517545A1
(de)
|
2012-12-31 |
2019-07-31 |
Neurimmune Holding AG |
Rekombinante menschliche antikörper zur therapie und vorbeugung von erkrankungen im zusammenhang mit polyomavirus
|
AU2013205589A1
(en)
|
2013-03-08 |
2014-09-25 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and associated epitope sequences
|
US9872899B2
(en)
|
2013-03-15 |
2018-01-23 |
Biological Mimetics, Inc. |
Immunogenic human rhinovirus (HRV) compositions
|
US10280221B2
(en)
|
2013-03-15 |
2019-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
US9920377B2
(en)
|
2013-03-15 |
2018-03-20 |
Sutter West Bay Hospitals |
FALZ for use as a target for therapies to treat cancer
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
EP3030902B1
(de)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
Neues screening-verfahren zur behandlung von friedreich-ataxie
|
TWI592426B
(zh)
|
2013-08-13 |
2017-07-21 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
KR20160035077A
(ko)
|
2013-08-13 |
2016-03-30 |
사노피 |
플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
|
US20150118249A1
(en)
|
2013-10-24 |
2015-04-30 |
Medimmune, Llc |
Stable, Aqueous Antibody Formulations
|
EP3110974A4
(de)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015231155B2
(en)
|
2014-03-21 |
2020-11-12 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
WO2015153916A1
(en)
|
2014-04-04 |
2015-10-08 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
EP3142700B1
(de)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
|
EP3154579A1
(de)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
Neue behandlung gegen das influenzavirus
|
JP6655074B2
(ja)
|
2014-06-20 |
2020-02-26 |
ジェネンテック, インコーポレイテッド |
シャガシンに基づく足場組成物、方法及び使用
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
EP3197557A1
(de)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats und brustrkrebs
|
CN108064248B
(zh)
|
2014-09-30 |
2022-03-15 |
生物控股有限公司 |
人源抗二肽重复(dpr)抗体
|
CA2965678A1
(en)
|
2014-10-31 |
2016-05-06 |
Medimmune, Llc |
An improved manufacturing method
|
DK3229838T3
(da)
|
2014-12-11 |
2020-10-19 |
Pf Medicament |
Anti-C10orf54-antistoffer og anvendelser deraf
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
CN107427590B
(zh)
|
2015-02-02 |
2021-08-31 |
伯明翰大学 |
具有多个t细胞表位的靶向部分肽表位复合物
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
CA2982400C
(en)
|
2015-03-31 |
2023-10-24 |
Medimmune Limited |
A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
|
RU2760582C2
(ru)
|
2015-09-02 |
2021-11-29 |
Иммутеп С.А.С. |
Анти-LAG-3 антитела
|
WO2017048902A1
(en)
|
2015-09-15 |
2017-03-23 |
Board Of Regents, The University Of Texas System |
T-cell receptor (tcr)-binding antibodies and uses thereof
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
RU2766000C2
(ru)
|
2016-01-08 |
2022-02-07 |
АльтруБио Инк. |
Четырехвалентные антитела к psgl-1 и их применения
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
CN110198729A
(zh)
|
2016-09-09 |
2019-09-03 |
豪夫迈·罗氏有限公司 |
卷曲蛋白的选择性肽抑制剂
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
EP3618865A4
(de)
|
2017-05-05 |
2021-05-05 |
Vaccinex, Inc. |
Menschlicher anti-semaphorin-4d-antikörper
|
WO2018226992A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
EP3668886A2
(de)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Peptidinhibitoren der tau-aggregation
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
AU2018371271A1
(en)
|
2017-11-27 |
2020-06-11 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
IT201900000651A1
(it)
|
2019-01-16 |
2019-04-16 |
Pastore Lucio |
Tecnologia di trasferimento genico
|
CA3130103A1
(en)
|
2019-02-13 |
2020-08-20 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
WO2020206063A1
(en)
|
2019-04-03 |
2020-10-08 |
Genzyme Corporation |
Anti-alpha beta tcr binding polypeptides with reduced fragmentation
|
TW202110881A
(zh)
|
2019-05-24 |
2021-03-16 |
法商賽諾菲公司 |
治療全身性硬化症之方法
|
EP4010372A2
(de)
|
2019-08-06 |
2022-06-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Biopharmazeutische zusammensetzungen und zugehörige verfahren
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022153195A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
EP4277664A1
(de)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Antikörper-pyrrolobenzodiazepinderivat-konjugat
|
CA3209052A1
(en)
|
2021-02-19 |
2022-08-25 |
Rafael Cristian CASELLAS |
Single domain antibodies that neutralize sars-cov-2
|
CA3220227A1
(en)
|
2021-05-28 |
2022-12-01 |
Matthew Bruce |
Combination therapies for treating cancer
|
EP4359430A2
(de)
*
|
2021-06-23 |
2024-05-01 |
Lycia Therapeutics, Inc. |
Bifunktionelle verbindungen, die igf-2-polypeptide enthalten
|
CN117794954A
(zh)
|
2021-08-03 |
2024-03-29 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和稳定同位素标记肽图谱方法
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023114951A1
(en)
|
2021-12-17 |
2023-06-22 |
Viiv Healthcare Company |
Combination therapies for hiv infections and uses thereof
|
US20230348604A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024083945A1
(en)
|
2022-10-20 |
2024-04-25 |
Glaxosmithkline Intellectual Property (No.3) Limited |
Antigen binding proteins
|